Physician profile
Alexander Markovich
NPI 1255464590
$1,055.42
in general payments reported to CMS, 2019-2025
19 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $110 · 2021: $126 · 2022: $208 · 2023: $159 · 2024: $106 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $400 · Education: $0.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.28 |
| Education | $0.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $150.28 | 2020-2023 | Terlivaz, Acthar |
| Astrazeneca Pharmaceuticals LP | $126.38 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $119.36 | 2021-2025 | |
| Akebia Therapeutics INC | $112.24 | 2020-2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $99.72 | 2019-2021 | |
| Amgen INC. | $59.93 | 2019-2022 | |
| Horizon Therapeutics Plc | $54.74 | 2022-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $52.70 | 2020-2023 | Velphoro |
| Opko Pharmaceuticals, LLC | $51.81 | 2019 | |
| Aurinia Pharma U.S., INC. | $43.68 | 2022-2025 | Lupkynis |
| Ardelyx, INC. | $27.50 | 2024 | Ibsrela |
| Travere Therapeutics, INC. | $25.86 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $25.59 | 2025 | |
| Glaxosmithkline, LLC. | $20.99 | 2021 | |
| Boston Scientific Corporation | $19.97 | 2023 | Lithovue |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.90 | 2025 | Ozempic |
| Vifor Pharma, INC. | $16.65 | 2019 | |
| Calliditas Therapeutics US INC. | $14.39 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Markovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.